FDA 522 Sample Size & Timeline Calculator

Interactive Calculator

Estimate Sample Size & Timeline

Section 522 surveillance execution is not just a statistical exercise. It is an operational system where protocol design, site activation, retention practices, and reporting cadence all interact. When teams under-specify sample size, they often chase late protocol amendments or unplanned site expansion. When teams over-specify sample size without operational feasibility, budgets become uncompetitive and timelines drift under attrition pressure.

This calculator uses a proportion-based approximation that is useful for early planning. It is intentionally simple enough for cross-functional discussion while explicit enough to show how sensitive your plan is to event-rate uncertainty, confidence choices, and allowable precision. The output should never replace formal biostatistical design, but it should absolutely shape governance and vendor decisions.

In practice, the biggest value comes from scenario comparison. A single number is rarely helpful. Instead, run three scenarios: base case, conservative, and stress case. Then evaluate whether your organization can absorb the stress case without emergency re-planning. If the answer is no, your initial design is operationally fragile even if the base case looks mathematically neat.

Expected Event Rate

Event-rate assumptions influence required sample size nonlinearly. Teams often set event rates from published studies that do not mirror real-world usage patterns. If field behavior differs from controlled studies, your observed event rate can shift quickly, forcing timeline and budget rework.

Margin of Error

Tighter margins drive larger samples. While tighter precision can improve confidence in interpretation, it also increases burden on enrollment, monitoring, data management, and patient retention. The right margin is a strategic decision, not purely a statistical preference.

Confidence Level

Confidence settings communicate uncertainty tolerance. Higher confidence levels require larger samples and can reduce schedule resilience when enrollment underperforms. Many teams default to 95% without stress-testing operational implications against realistic monthly enrollment.

Attrition Allowance

Attrition is routinely under-budgeted. In distributed real-world settings, retention variance can be larger than expected because follow-up friction often emerges late. A well-run plan includes conservative attrition assumptions from the start and explicit mitigation tactics tied to known dropout drivers.

Enrollment Pace and Follow-up Duration

Enrollment speed is where optimism bias appears first. Site initiation delays, training variation, and referral bottlenecks can all reduce throughput. Follow-up duration compounds this challenge because overall completion is constrained by both accrual and longitudinal retention.

Reliable timeline delivery requires more than adding sites when enrollment is slow. High-performing teams establish an operating architecture with measurable levers. These include prequalified backup sites, centralized query triage targets, retention outreach standards, and governance rules that trigger intervention before schedule damage becomes irreversible.

One practical approach is to define three control thresholds before launch: yellow for mild underperformance, orange for sustained underperformance, and red for materially compromised schedule confidence. Each threshold should map to pre-approved actions such as adding sites, adjusting outreach intensity, or reallocating monitoring resources.

Equally important is decision latency. Teams sometimes detect underperformance quickly but delay escalation because ownership is ambiguous. A strong governance model names a single accountable lead for schedule health and requires timeline-impact decisions within a defined window, not after prolonged cross-functional debate.

If you use external providers, include these threshold rules in statements of work and performance dashboards. Without explicit threshold-based interventions, sponsors frequently discover avoidable delays only after a missed milestone is already locked in.

Mathematical sufficiency does not guarantee interpretive sufficiency. A study can hit target sample size and still produce weak regulatory confidence if data completeness, endpoint consistency, or subgroup interpretability are poor. This is why sample planning should be integrated with endpoint operationalization and data quality architecture.

For example, if endpoint capture depends on site-level interpretation with weak standardization, larger sample size may not compensate for measurement inconsistency. Similarly, if protocol execution quality varies significantly across sites, nominal enrollment volume can obscure signal clarity rather than improve it.

A practical safeguard is to pair sample-size estimates with quality assumptions: expected missingness, query burden, adjudication complexity, and site heterogeneity. If these factors are high, teams should avoid overconfidence in raw sample targets and prioritize process controls that protect interpretability.

Sponsors that ignore this connection often spend heavily to recruit participants, then underdeliver in evidence clarity because data operations were not designed for surveillance-grade consistency.

Expertise: The page is designed for regulatory and clinical leaders who need operationally grounded sample and timeline assumptions, not abstract formulas detached from execution realities.

Experience: The planning recommendations reflect recurring execution patterns in device programs: enrollment optimism, underestimated attrition, and delayed escalation governance.

Authority: Primary citations anchor assumptions in FDA and eCFR frameworks relevant to postmarket surveillance obligations.

Trust: The calculator is transparent about limitations and encourages formal statistical review for final protocol decisions.

Most teams know they should run scenarios, but the scenarios are often too close together to be decision-useful. A practical design is to separate scenarios with meaningful operational differences. For example, if base enrollment is 30 patients per month, a conservative scenario might be 22 and a stress scenario might be 16. If those values are too close, they will not reveal true schedule sensitivity.

Pair each scenario with an intervention playbook. The conservative scenario might trigger additional site activation and tighter retention monitoring. The stress scenario might trigger leadership-level escalation, budget release, and protocol-level adjustments. If actions are not predefined, scenario analysis becomes descriptive rather than actionable.

Teams should also identify inflection points where timeline confidence changes sharply. A common inflection point is sustained under-enrollment across two review cycles. Another is a sudden increase in missing endpoint data. By defining inflection points early, you reduce reaction delay and preserve final evidence quality.

Scenario planning is not about predicting the future exactly. It is about ensuring your operating model can absorb realistic uncertainty without quality compromise.

Timeline planning is usually treated as an enrollment math problem, but data quality can become the dominant delay source in mature phases of execution. Query backlog, inconsistent endpoint interpretation, and late adjudication can push reporting milestones even when enrollment is on track. Sponsors should therefore model quality effort explicitly alongside accrual metrics.

One proven method is to track a quality burden index with three components: unresolved query volume, endpoint adjudication lag, and missingness in critical variables. If this index rises beyond predefined thresholds, teams should classify timeline risk as elevated even if accrual remains nominally healthy.

This integrated view prevents false confidence and improves resource allocation. Without it, teams may celebrate accrual progress while quietly accumulating quality debt that later delays interim and final outputs. In surveillance programs, late quality correction is usually more expensive than early prevention.

When comparing providers, ask how they instrument quality burden and how quickly they escalate when indicators move out of tolerance. Strong providers can show specific response windows, not general commitments.

Is this calculator enough for final protocol sign-off?

No. It is a planning tool for early assumptions and cross-functional alignment. Final study design should include qualified biostatistical review and protocol-specific rationale.

Should we plan on one scenario or multiple scenarios?

Always run multiple scenarios. At minimum: base, conservative, and stress. The stress scenario is usually the one that determines whether your plan is resilient.

How often should we revisit assumptions?

At least monthly during startup and quarterly during stable execution, with immediate re-evaluation after major deviations in enrollment pace, retention, or endpoint capture quality.

Where does provider selection fit?

After assumptions are explicit. Use the output to compare +50 providers using common scenario definitions so proposals are comparable and scope variance is visible.

• [1] FDA, Section 522 overview: official page
• [2] eCFR, 21 CFR Part 822: regulatory text
• [3] FDA, postmarket safety and MDR resources: medical device safety

• Validate enrollment assumptions with current site readiness, not historical averages from unrelated programs.
• Document how attrition assumptions were chosen and what mitigation actions are pre-approved.
• Define quality-burden thresholds that can override optimistic accrual signals.
• Align provider dashboards with internal governance metrics before launch.
• Predefine escalation windows so corrective decisions happen in days, not months.

Teams that complete this checklist usually reduce avoidable timeline churn and improve forecast credibility with leadership.

• 522 Applicability & Risk Calculator
• 522 Study Budget Calculator
• 522 Site Feasibility Calculator
• 522 Protocol Amendment Impact Calculator
• 522 Data Quality Remediation Calculator
• Compare +50 FDA 522 providers